Consecutive Fecal Calprotectin Measurements to Predict Relapse in Patients with Ulcerative Colitis Receiving Infliximab Maintenance Therapy
| Autor: | Idar Lygren, Jonas Koch, Severine Vermeire, Geert DʼHaens, Filip Baert, Jørgen Jahnsen, Inger Camilla Solberg, Edouard Louis, Fernand Fontaine, Tore Grimstad, Roald Torp, Lars Normann Karlsen, Olivier Dewit, D Staessen, Martine De Vos, Jean-Claude R J Coche, Fazia Mana, Guy Lambrecht, Vinciane Muls, Maja Noman, Thomas de Lange, Bert Vander Cruyssen, Philippe M R Potvin, Gert A. Van Assche, Pieter Hindryckx, André Van Gossum, Magne Henriksen, Cool M, Jacques Belaiche, Jo G P Vandervoort, Jean-Marc Maisin, Denis Franchimont, Eirik Kittang, Bart Neuville, Arnaud Collard, Philippe Van Hootegem, Tom G. Moreels |
|---|---|
| Přispěvatelé: | AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Gastroenterology and Hepatology |
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male medicine.medical_specialty Enzyme-Linked Immunosorbent Assay Inflammatory bowel disease Gastroenterology Feces Young Adult fluids and secretions Maintenance therapy Recurrence Internal medicine medicine Humans Immunology and Allergy Longitudinal Studies Prospective Studies Colitis Prospective cohort study Sigmoidoscopy Aged biology business.industry Anti-Inflammatory Agents Non-Steroidal Remission Induction C-reactive protein Antibodies Monoclonal Middle Aged Prognosis medicine.disease Ulcerative colitis Infliximab Surgery Area Under Curve biology.protein Colitis Ulcerative Female Human medicine Calprotectin business Leukocyte L1 Antigen Complex Biomarkers Follow-Up Studies medicine.drug |
| Zdroj: | Inflammatory bowel diseases Inflammatory bowel diseases, 19(10), 2111-2117. John Wiley and Sons Inc. |
| ISSN: | 1078-0998 |
| Popis: | Background:This study examined whether fecal calprotectin can be used in daily practice as a marker to monitor patients with ulcerative colitis (UC) receiving infliximab maintenance therapy.Methods:This prospective multicenter study enrolled adult patients with UC in clinical remission under infliximab maintenance therapy. Fecal calprotectin levels were measured every 4 weeks. Sigmoidoscopies were performed at inclusion and at study end. Relapse was defined as a clinical need for change in treatment or an endoscopic Mayo subscore of 2 at week 52. Sustained deep remission was defined as a partial Mayo score 300 mg/kg) already 3 months before the flare. Further receiver operator curve analysis suggested that a calprotectin level >300 mg/kg had a reasonable sensitivity (58.3%) and specificity (93.3%) to model flare. Two consecutive calprotectin measurements of >300 mg/kg with 1-month interval were identified as the best predictor of flare (61.5% sensitivity and 100% specificity).Conclusions:Fecal calprotectin can be used in daily practice to monitor patients with UC receiving infliximab maintenance therapy. Two consecutive measurements >300 mg/kg is more specific than a single measurement for predicting relapse. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|